Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04856884 in Recurrent Glioblastoma
NCT01225510Phase 2Withdrawn
- Sponsor
- Pfizer
- Start
- Jan 2011
- Primary completion
- Jan 2013
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of PF-04856884 in glioblastoma (GBM), sponsored by Pfizer. Planned start Jan 2011; status: withdrawn.
02
Drugs
PF-04856884
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01225510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01225510.